STOCK TITAN

Atea Pharmaceuticals (AVIR) Stock News

AVIR NASDAQ

Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.

Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.

Rhea-AI Summary

Atea Pharmaceuticals (AVIR) reported a narrower third-quarter net loss and advanced its hepatitis pipeline alongside a new credit facility. Net loss was $32.162 million, or $0.40 per share, versus $42.049 million, or $0.53 per share, a year earlier. Cash and investments totaled $191.199 million at September 30, 2026, versus $301.830 million at year-end 2025.

Phase 3 C-BEYOND met primary and secondary endpoints, demonstrating statistical non-inferiority of bemnifosbuvir/ruzasvir to Epclusa for hepatitis C. Atea expects C-FORWARD results in early 2027 and targets a US approval application in mid-2027. Its hepatitis E candidate AT-587 advanced into multiple-dose testing. Atea drew $65 million at the November 6 closing of a Hercules Capital facility offering up to $200 million; additional borrowing requires specified milestones and other conditions. Atea expects current resources to fund planned operations into mid-2028.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) entered a credit facility with Hercules Capital for up to $200 million to support its antiviral programs. Atea received $65 million at closing; further funding depends on milestones, agreement terms or lender discretion. The facility matures in 60 months, with a 48-month interest-only period that can extend to 60 months upon a specified commercial milestone.

Atea expects existing cash and investments plus the initial borrowing to fund planned operations into mid-2028. It expects results from its second Phase 3 hepatitis C trial, C-FORWARD, in early Q1 2027 and plans a US marketing application for bemnifosbuvir/ruzasvir in mid-2027. Its US launch goal is 2028, if approved; the financing also supports its hepatitis E clinical program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
none
-
Rhea-AI Summary

Atea Pharmaceuticals (AVIR) will host its third-quarter 2026 financial results and business update conference call on November 9, 2026. The live call and audio webcast will begin at 4:30 p.m. ET and cover the quarter ended September 30, 2026. A webcast archive will be available on the company’s website approximately two hours after the call and remain available for at least 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.71%
Tags
conferences earnings date
Rhea-AI Summary

Atea Pharmaceuticals (AVIR)/b) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 12:20 p.m. EDT in New York, NY. Chief Executive Officer and Founder Jean-Pierre Sommadossi, PhD, and other members of the management team are scheduled to participate. A live webcast of the presentation will be accessible via the company’s investor relations website, with an archived version available for at least 90 days after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.57%
Tags
none
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) reported second quarter 2026 results and key viral hepatitis pipeline progress. The Phase 3 C-BEYOND trial of bemnifosbuvir/ruzasvir (BEM/RZR) for HCV met its primary and secondary non-inferiority endpoints versus sofosbuvir/velpatasvir, with sustained virologic response (SVR) of 93.9% vs. 94.8% in the mITT population (n=905). Non‑cirrhotic patients achieved a 93.5% SVR with 8 weeks of BEM/RZR vs. 94.6% with 12 weeks of SOF/VEL; cirrhotic patients had 95.4% SVR in both arms. BEM/RZR was generally safe and well tolerated with no drug‑related serious adverse events.

Atea completed enrollment of its second Phase 3 trial, C-FORWARD, with over 880 patients across 17 countries and expects topline data in early Q1 2027, targeting an NDA submission in Q2 2027. A first‑in‑human Phase 1 trial of AT‑587 for chronic HEV started in July. At June 30, 2026, cash, cash equivalents and marketable securities were $219.5 million (vs. $301.8 million at December 31, 2025). Q2 2026 research and development expense was $28.2 million (down from $32.3 million), general and administrative expense was $6.9 million (down from $9.1 million), and net loss was $32.9 million, or $0.41 per share, compared to $37.2 million, or $0.44 per share, a year earlier.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.20%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results and provide a business update. Investors can access the webcast via the Investor Relations section of Atea’s website under “Events and Presentations,” or join by telephone using the U.S. number 1-877-407-0779, international number 1-201-389-0914, and conference ID 13761501. An archived webcast will be available on the company’s website approximately two hours after the call and will remain accessible for at least 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
conferences earnings date
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline Phase 3 C-BEYOND results in North America for its once-daily fixed-dose combination bemnifosbuvir/ruzasvir (BEM/RZR) in chronic hepatitis C virus (HCV). In the modified intent-to-treat population (n=905), BEM/RZR achieved a 93.9% sustained virologic response (SVR) at Week 24 versus 94.8% for standard-of-care sofosbuvir/velpatasvir (SOF/VEL; Epclusa), meeting the primary endpoint of statistical non-inferiority within a prespecified 5% margin.

In patients without cirrhosis (n=721), 8 weeks of BEM/RZR achieved a 93.5% SVR versus 12 weeks of SOF/VEL with 94.6% SVR. In patients with cirrhosis (n=184), 12 weeks of each regimen yielded 95.4% SVR in both arms. Secondary endpoints, including per-protocol analysis, also met statistical non-inferiority. BEM/RZR was generally safe and well tolerated, with no drug-related serious adverse events or drug-related early discontinuations and safety comparable between arms. C-FORWARD, the companion Phase 3 trial outside North America with more than 880 patients enrolled, remains on track to report topline results in early 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) has initiated a first-in-human Phase 1 clinical trial of AT-587, an oral nucleotide analog in development for hepatitis E virus (HEV), a serious liver disease with no approved therapies and high risk for immunocompromised patients, including transplant recipients.

The randomized, double-blind, placebo-controlled study in healthy volunteers features single ascending dose, multiple ascending dose, and food-effect components, with dose escalation guided by emerging safety and pharmacokinetic data. Preclinical results presented at EASL 2026 showed AT-587 is 30–150 times more potent in vitro against HEV than sofosbuvir and ribavirin, demonstrated in vivo activity in an HEV genotype 3 gerbil model, showed no in vitro toxicity, exhibited activity against several other viruses, and retained potency against ribavirin and sofosbuvir resistance strains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
-
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) completed patient enrollment in C-FORWARD, its Phase 3 trial outside North America evaluating the oral combination of bemnifosbuvir and ruzasvir (BEM/RZR) for chronic hepatitis C virus (HCV).

C-FORWARD enrolled over 880 treatment‑naïve patients at ~120 sites in 17 countries, comparing BEM/RZR with sofosbuvir/velpatasvir. Topline results are expected around year-end 2026, with C-BEYOND topline data on track for mid‑2026. The program is described by Atea as the first global Phase 3 head‑to‑head DAA regimen comparison for HCV.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.90%
Tags
Rhea-AI Summary

Atea Pharmaceuticals (Nasdaq: AVIR) reported Phase 1 data showing its fixed-dose hepatitis C regimen bemnifosbuvir/ruzasvir (BEM/RZR) has a low risk of drug-drug interactions with common medicines including omeprazole, digoxin and rosuvastatin.

Atea also presented preclinical data for AT-587, a potential first-in-class hepatitis E antiviral with high in vitro potency and in vivo efficacy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none

FAQ

What is the current stock price of Atea Pharmaceuticals (AVIR)?

Atea Pharmaceuticals (AVIR) last closed at $3.93.

What is the market cap of Atea Pharmaceuticals (AVIR)?

The market cap of Atea Pharmaceuticals (AVIR) is approximately $315.6M.